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STUDY OF DRUG DELIVERY BEHAVIOR THROUGH  
BIOMEMBRANES  USING THERMAL AND BIOANALYTICAL TECHNIQUES 
HAREESHA REDDY VENUMUDDALA 
ABSTRACT 
     This Master of Science thesis encompasses two projects in chemical pharmaceuticals. 
The first is a study of excipients and the added new information collected beyond 
Thermal Gravimetric Analysis and Differential Scanning Calorimetry from Dielectric 
Analysis.  These new properties enhance our global knowledge of excipients by thermal 
analytical methods. Excipients, the inactive ingredients in formulated drugs, aid different 
functions of the active pharmacy ingredient, the drugs. Low temperature transitions, by 
DEA including melting of frozen solvents, e.g. water, are more definitive than observed 
by low temperature DSC.  
     Millions of dollars are expended annually on pharmaceutical testing to qualify 
excipients for fully formulated drugs, medicines and active ingredients. To understand 
the action of the excipients in the human body at body temperature of 37°C, the study of 
their individual and interactive properties are desirable. DEA DSC and Thermal 
Gravimetric analysis (TGA) methods are employed to screen the most widely used drug 
excipients. In this study the following excipients were examined by DEA: cotton seed oil, 
mannitol, peanut oil, polyethylene glycol, sugar, sodium lauryl sulfate, sodium starch 
glycolate, sodium stearate, canola oil, and anhydrous lactose, benzoic acid and vanillin. 
The comparison of DSC and DEA thermal curves for each excipient indicates that major 
endothermic events have occurred e.g., volatilization or melting of the excipient are 
viewed as fundamental DEA properties. These properties are the rise in permittivity and 
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dielectric loss factor. The focus of this project was to learn to prepare, examine and 
interpret the resulting variations.  
     The electrical conductivity (e‖ * frequency* constant), permittivity (e’) and tan delta 
value (e‖/e’) are used to enhance the characterization of the excipient.   
     The second, and major project for this thesis, is to evaluate bipolar disorder drug 
transport with and without an applied electric field of 10V mm⁻¹. Drug delivery was 
tested with several animal models, dry shed snake skins and a moist pig skin, which will 
be used to develop a new transdermal patch. Characterization of appropriate drugs by 
DEA and other thermal analytical methods will aid the understanding of chemical 
stability and interactions .These properties will aid a Bipolar Disorder (BPD) patient to 
receive their correct dosage in a timely manner and improve patient compliance. BPD 
also called as Manic Depressive Disorder results in extreme shifts in mood and behavior 
that may last for weeks or months, causing severe disturbances in the lives of those 
affected. A high percentage of BPD is untreated due to the lack of a well-tolerated and 
effective drug transport therapy. So, the analysis of the selected drugs by thermal 
analytical techniques gives support to understand the transport properties. Studying the 
transport properties of these drugs through a transdermal route may pave the way for a 
novel transdermal drug delivery method. In this study, Dielectric Analysis (DEA) is used 
to characterize and evaluate the transport properties of the selected drugs (Olanzapine, 
Risperidone, and Quetiapine Fumarate). Dielectric Analysis implements drug delivery 
employing an AC frequency, modulating drugs of a wide molecular weight range (e.g. 
300 to 30,000 Daltons) with an interdigitated electrode system. In this analysis, the drugs 
were studied using animal models (Shed snake skin and pig skin). There is a specific 
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frequency we discovered for each drug, where the change in the electric profile begins 
which ―aids the delivery‖. The delivery is measured by enhanced conductivity and is 
paralleled with increased drug throughput tracked by UV analysis. 
 
vii 
 
TABLE OF CONTENTS 
PAGES 
ACKNOWLEDGEMENTS………………………………………………………………iii 
ABSTRACT……………………………………………………………………………...iv 
LIST OF FIGURES.............................................................................................................x 
LIST OF TABLES............................................................................................................xiv 
ABBREVIATIONS...........................................................................................................xv 
OBJECTIVES ………………………………………………………………...................01 
HYPOTHESIS...................................................................................................................03 
PROTOCOL..............................................................…………………………………....04 
CHAPTERS 
      I. INTRODUCTION....................................................................................................06 
      II. INSTRUMENTS AND METHODS.......................................................................10 
            2.1 Differential Scanning Calorimetry...................................................................10 
2.1.1 Instrument...............................................................................................11 
2.1.2 Calibration...............................................................................................12 
2.1.3 Sampling.................................................................................................12 
2.1.4 Procedure ............................ ..................................................................13 
2.2 Dielectric Analysis...........................................................................................14 
2.2.1 Calibration...............................................................................................15 
                  2.2.2 Instrument …………………..........……………………………………16 
2.2.3 Procedure................................................................................................17 
2.3 Thermal Gravimetric Analysis (TGA).............................................................17 
viii 
 
2.3.1 Instrument...............................................................................................17 
2.3.2 Sampling and Procedure ........................................................................18 
III. DIELECTRIC ANALYSIS ENHANCES CHARACTERIZATION OF 
PHARMACEUTICAL EXCIPIENTS 
3.1 Abstract............................................................................................................19 
3.2 Introduction......................................................................................................20 
3.3 Experimental…………………………………………………………………22 
                 3.3.1 Materials Used..................................................................................…...22 
                 3.3.2 Methods....................................................................................…............23 
3.4 Results and Discussion....................................................................................23 
3.5 Conclusions......................................................................................................30 
3.6 Further Studies.................................................................................................31 
3.7 References........................................................................................................31 
      IV. CHARACTERIZATION AND EVALUATION OF ATYPICAL               
ANTIPSYCHOTICS FOR TRANSDERMAL DELIVERY BY DIELECTRIC 
ANALYSIS AND ULTRAVIOLET-VISIBLE SPECTROSCOPY 
4.1 Abstract............................................................................................................33 
4.2 Introduction......................................................................................................34 
4.3 Materials and Methods ...........................................................................…....37 
      4.3.1 Drugs.......................................................................................................37 
                  4.3.2 Skin Membranes ......................................................................…..........37 
      4.3.3 Experimental Methods............................................................................38 
4.4 Results and Discussion....................................................................................41 
ix 
 
                  4.4.1 DSC Evaluation.............................................................................….....41 
                  4.4.2 Dielectric Analysis.........................................................................….....43 
                  4.4.3 Spectroscopic evidence of drug delivery through the animal model 
membrane............................................................................................ .45 
4.5 Conclusions......................................................................................................47 
4.6 References........................................................................................................47 
      V. TRANSDERMAL DELIVERY: CHARACTERIZATION OF BIPOLAR 
DISORDER DRUGS AND STUDY OF THEIR TRANSPORT THROUGH 
BIOMEMBRANES 
5.1 Introduction......................................................................................................50 
5.2 Procedure.........................................................................................................55 
5.3 Results and Discussion....................................................................................57 
                  5.3.1 DSC Evaluation ..............................................................…...................57 
                  5.3.2 Dielectric Analysis ….............................................................................61 
                        5.3.2.1 Snake skin…..................................................................................61 
                             5.3.2.2 Pig skin…………………………………………………………..75 
5.4 Conclusions......................................................................................................86 
VI. FUTURE DIRECTIONS …………………………………………......…………88 
REFERENCES......................................................................................................89 
 
 
 
x 
 
 LIST OF FIGURE 
FIGURES                                                                                                                                          PAGE 
1 Differential Scanning Calorimeter 11 
2 Solid fat index (SFI) pans used for DSC; left- pan, right- lid 11 
3 Heat-Cool-Heat cycle of Acetanilide with Tm, Tmp, ∆Hf, Tc, Tcp, ∆Hc 14 
4 Dielectric Analyzer (DEA) 15 
5 Benzoic acid DSC and 100Hz Ion Conductivity DEA 25 
6 TGA of Benzoic acid 25 
7 Mannitol TGA, DSC and 100Hz DEA Ionic Conductivity 26 
8 Mannitol structure 27 
9 Mannitol DSC and 100Hz DEA Ionic conductivity 27 
10 Anhydrous Lactose DSC, TGA and 10Hz Permittivity DEA 28 
11 Calcium Phosphate DSC, TGA and 100Hz Ionic conductivity 30 
12 Shed skin of Boa 38 
13 Solid fat index (SFI) pans 39 
14 Single surface gold ceramic sensor 40 
15 Drug on top of snake skin 40 
16 DSC profile of Risperidone with melting temperature 42 
17 Dielectric profile of Olanzapine, isothermal at 37°C for 40 min 43 
18 Olanzapine DEA profile before change 44 
19 Olanzapine DEA profile after change 44 
20 Olanzapine calibration curve 46 
21 Chemical structure of Olanzapine 52 
xi 
 
22 Chemical structure of Risperidone 53 
23 Chemical structure of Quetiapine Fumarate 54 
24 Shed snake skin 54 
25 Single surface electrode 56 
26 Shed snake skin with drug 57 
27 DSC profile of Olanzapine 58 
28 DSC profile of Risperidone 59 
29 DSC profile of Quetiapine Fumarate 59 
30 DEA profile of Olanzapine at 10 min; 30,000Hz; Iso at 37°C for 40 min 61 
31 DEA profile of Olanzapine at 10 min; before change 62 
32 DEA profile of Olanzapine at 10 min after change 62 
33 DEA profile of Olanzapine; 30,000Hz, Iso at 37°C for 40 min; 20 min 63 
34 DEA profile of Olanzapine at 20 min; before change 63 
35 DEA profile of Olanzapine at 10 min; after change 64 
36 DEA profile of Olanzapine at 35 min; 30,000Hz; Iso at 37°C for 40 min 64 
37 DEA profile of Olanzapine at 35 min; before change 65 
38 DEA profile of Olanzapine at 10 min; after change 65 
39 DEA profile of Risperidone at 10 min; 30,000Hz; Iso at 37°C for 40 min 66 
40 DEA profile of Risperidone at 10 min; before change 66 
41 DEA profile of Risperidone at 10 min; after change 67 
42 DEA profile of Risperidone at 20 min; 30,000Hz; Iso at 37°C for 40 min 67 
43 DEA profile of Risperidone at 20 min; before change 68 
44 DEA profile of Risperidone at 20 min; after change 68 
xii 
 
45 DEA profile of Risperidone at 35 min; 30,000Hz; Iso at 37°C for 40 min 69 
46 DEA profile of Risperidone at 35 min; before change 69 
47 DEA profile of Risperidone at 35; after change 70 
48 DEA profile of Quetiapine Fumarate at 10 min; 30,000Hz; Iso at 37°C for 40   
min 70 
49 DEA profile of Quetiapine Fumarate at 10 min; before change 71 
50 DEA profile of Quetiapine Fumarate at 10 min; after change 71 
51 DEA profile of Quetiapine Fumarate at 20 min; 30,000Hz; Iso at 37°C for 40   
min 72 
52 DEA profile of Quetiapine Fumarate at 20 min; before change 72 
53 DEA profile of Quetiapine Fumarate at 20 min; after change 73 
54 DEA profile of Quetiapine Fumarate at 35 min; 30,000Hz; Iso at 37°C for 40    
min                                                                                                                         73 
55 DEA profile of Quetiapine Fumarate at 35 min; before change 74 
56 DEA profile of Quetiapine Fumarate at 35 min; after change 74 
57 DEA profile of Olanzapine at 10 min; 30,000Hz; Iso at 37°C for 40 min 75 
58 DEA profile of Olanzapine at 20 min; 30,000Hz; Iso at 37°C for 40 min 76 
59 DEA profile of Olanzapine at 35 min; 30,000Hz; Iso at 37°C for 40 min 76 
60 DEA profile of Risperidone at 20 min; 30,000Hz, Iso at 37°C for 40 min 77 
61 DEA profile of Risperidone at 35 min; 30,000Hz; Iso at 37°C for 40 min 77 
62 DEA profile of Quetiapine Fumarate at 10 min; 30,000Hz; Iso at 37°C for 40   
min 78 
xiii 
 
63 DEA profile of Quetiapine Fumarate at 20 min; 30,000Hz; Iso at 37°C for 40   
min 78 
64 DEA profile of Quetiapine Fumarate at 35 min; 30,000Hz; Iso at 37°C for 40   
min 79 
65 Olanzapine stock solution- peak observed at 363nm 80 
66 Olanzapine test sample solution- peak observed at 362nm 80 
67 Risperidone standard stock solution scan- peak observed at 280nm 81 
68 Risperidone test solution scan- peak observed at 282 81 
69 Quetiapine Fumarate stock solution scan- peak observed at 303nm 82 
70 Quetiapine Fumarate test solution scan- peak observed at 303nm 82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
LIST OF TABLES 
TABLES                                                                                                                     PAGE 
1 List of excipients studied 7 
2 List of BPD drugs studied 9 
3 List of Excipients 22 
4 List of drugs studies 37 
5 Thermal properties of drugs by DSC 42 
6 Analysis of DEA data to rank drug transport for the 3 drugs in shed snake skin 45 
7 End-point conductivity and throughput 46 
8 BPD drugs studied 51 
9 DSC thermal properties of BPD drugs 60 
10 Analysis of DEA curve slope data to rank drug transport in shed snake skin 75 
11 End-point conductivity and drug throughput of shed snake skin 83 
12 End-point conductivity and drug throughput in pig skin 84 
13 Drug throughput and conductivity - shed snake skin and pig skin 85 
14 Summary of results 86 
 
 
 
 
 
 
 
 
xv 
 
ABBREVIATIONS 
 
BPD- Bipolar Disorder 
Mol.Wt. - Molecular Weight 
DSC- Differential Scanning Calorimetry 
Tm - Onset Melting Temperature 
Tmp/Tp- Peak Melting Temperature 
∆Hf- Heat of Fusion 
Tg -Glass transition 
Tc- Onset Crystallization Temperature 
Tcp- Crystallization peak temperature 
∆Hc-Heat of Crystallization 
API’s- Active Pharmaceutical Ingredients 
DEA- Dielectric Analysis 
UV/vis- Ultraviolet-visible spectroscopy 
 
1 
 
OBJECTIVES 
     The main objective of this thesis was to characterize the selected drugs using Thermal 
Analysis and then relate the drug properties to the transport of the drugs transdermally. 
Later the evaluation of these drugs was accomplished by UV analysis and the data was 
correlated.  The electrical properties of the drugs were studied using Dielectric Analysis. 
Other physical property attributes were determined by Differential Scanning Calorimetry. 
Structural features were studied by Fourier Transform Infrared Spectrometry and Macro 
photography.  
     The initial phase of this thesis was the characterization of the selected chemical 
excipients by Thermal Analysis. This project was under taken as the groundwork for the 
later part of this study, where the Bipolar Disorder drugs were carefully evaluated. The 
excipients selected were screened by DEA, DSC and TGA and the data interpreted was 
compared and ranked. Excipients are the inactive pharmaceuticals that are used to make 
up a medication. They are used as adhesives, plasticizers, binders, disintegrates, 
dispersants and fillers. In this study, nine common excipients were measured by DSC and 
TGA. An additional new Thermal Analytical tool, DEA, added a significant amount of 
characterization data. DEA uniquely measures the electrical properties of the organic 
chemicals studied and revealed new physical-chemical properties, for example, electrical 
conductivity is a function of temperature and time. Detection of water melting at 0°C was 
observed by DEA and not DSC. The electrical conductivity of mannitol and anhydrous 
lactose was observed more than a 100°C below their melting temperature.  
     In the next phase of our study, the Bipolar Disorder drugs were screened by the above 
cited instrumental methods. The properties of these drugs were determined and were used 
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to identify and quantify the drugs used by the mentally ill. The major value of this 
research is to develop an AC electrified patch for Bipolar Disorder dosing. Patient 
compliance can be improved with knowledge of the drug dielectric transport properties as 
determined by DEA. 
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HYPOTHESIS 
     Transdermal drug delivery is becoming more preferable over the past decades due to 
its advantages over the oral systemic routes. Pharmacokinetic properties, drug 
bioavailability and patient compliance can be improved by transdermal procedures. 
Active ingredients in most of the well-known transdermal products are delivered through 
the skin by passive diffusion. Recently, an efficient drug delivery method using electric 
field has been developed as transdermal patches. This field based drug delivery transfers 
drugs at a controlled rate, which in turn improves patient compliance. Direct current (DC) 
is the most commonly used in the field based transdermal patches. However, these DC 
field based methods are associated with several compelling drawbacks including side 
effects which can potentially cause skin irritation and burning. Replacing the DC field 
with an AC field would be an ideal solution for these drawbacks. Preliminary studies 
using AC field in drug delivery by Riga et al yielded promising results and based on 
these studies we hypothesize that an efficient and effective drug delivery device for 
Bipolar Disorder (BPD) can be developed using AC field. The major advantage of the 
new development is that it overcomes the main side-effect of the DC method. Moreover, 
AC field provides less flux enhancement than DC field.            
     This new method based on AC field is validated using two model biomembranes, shed 
snake skin and porcine skin. The focus of this innovative technique is to improve patient 
compliance in the case of BPD. 
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PROTOCOL 
Drug Characterization by Physical – Analytical Techniques 
Overview 
 Characterization and evaluation of excipients  
 Characterizations of Bipolar Disorder drugs and evaluate their transport properties 
Scope 
 Purpose of the techniques: Quantitative and Qualitative (DEA and UV) 
 Define physical properties to be defined 
Terminology 
 Define all significant terms 
 Define all abbreviations 
Summary of Methods 
 Brief outline of each method 
 Brief statement of the test method principle 
Significance in Use 
 Relevance in meaning of each test method 
 Development of drug delivery patch 
 Development of new transdermal delivery route 
Methods 
 Differential Scanning Calorimetry 
 Dielectric Analysis 
 Ultraviolet –Visible spectrometry 
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Hazards 
 Care should be taken in handling specific drugs 
Calibration 
 Detailed instructions of calibration of the instrument are mentioned 
Procedure 
 Sequenced detailed directions 
 Describe successive steps for all the procedures 
Interpretation of results 
 Directions for evaluating the results 
 List of all the tables 
 Specify significant figures 
Research report 
 Detailed information required in reporting the results 
 Correlating the results 
References 
 References to publications supporting or providing needed information 
 Keywords: identify words, terms or phrases that best represent the technical 
information reported 
Conclusions 
 Summarize all collected data 
 Compare data from different methods 
 Site all relevant information 
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CHAPTER I 
INTRODUCTION 
 
 
     Pre-formulation studies are used for the characterization of drug substances and 
excipients
 
[1]. There is an ongoing need for technical information that describes physical 
and chemical properties of drugs and excipients in the development of formulations and 
manufacturing processes
 
[2]. Pre-formulation studies often include, crystal size and 
shape; polymorphism; drug permeability; pH-solubility profiles; pH-stability profiles; 
and screening for suitable excipients.     
     Thermal analysis and Microcalorimetry are key tools for purity evaluations, thermal 
and oxidative stability determination, and drug-excipient compatibility studies. Thermal 
analytical techniques are used to characterize the behavior of pharmaceutical samples as a 
function of temperature or time [3, 4]. These methods include DSC, DEA, and TGA [5, 
6]. DSC and TGA are continually used to study and characterize potential drug-drug, 
drug-excipient interactions using thermal analysis [7, 8].  
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     Polymorphism is the ability of a compound to crystallize in more than one distinct 
crystal structure. Polymorphs usually show different physiochemical behavior in 
properties of pharmacological interest such as: density, hardness, hygroscopic tendency, 
solubility, velocity, or thermal stability [12]. One polymorph can be converted into 
another under certain circumstances and can be characterized by DSC, TGA, and other 
combined techniques. The excipients used are listed in the Table 1. 
Table 1 List of excipients studied 
Excipient CAS Phase 
Melting Point 
(
o
C) 
Source 
Functional 
Category 
Benzoic 
Acid 
65-85-0 Solid 122 
Fisher 
Scientific  
Company 
Preservative 
Mannitol 69-65-8 Solid 165 Atlas Chem. 
Sweetening 
agent, 
Diluent 
Anhydrous 
Lactose 
63-42-3 Solid 223 
Eastman 
Organic 
Chemical 
Diluent, 
Filler 
Calcium 
Phosphate 
7756-87-4 Solid Decomp>100 
Amend Drug 
Chemicals 
Buffer, 
Glidant, 
Diluent 
*Decomp = Decomposition 
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     In the next phase, we studied the drug delivery behavior of the antipsychotic drugs 
used in Bipolar Disorder Dosing. 
      Bipolar disorder (BPD) is a widespread chronic disorder with recurrent episodes of 
mania and depression [13]. It accounts for 25% of all mental disorders. For many years, 
the conventional mood stabilizers such as lithium (as carbonate and citrate) and 
antidepressants have been used as a first choice of medication for the treatment of BPD 
patients before the evolution of newer medications [14-16]. Due to their long-term side 
effects, recently a new class of antipsychotic drugs, the atypical antipsychotics, has 
become effective with fewer side effects and better mood stabilizing properties [17]. It is 
very important for a bipolar disorder patient to take medications in a timely manner. 
Untimely discontinuation of the medications is the major complication to positive 
outcomes in individual bipolar disorder patients. Treatment adherence is a very important 
aspect to be considered and it is affected by various factors like age, gender, medication 
side effects and other environmental factors [13, 18and 19]. Another important factor to 
be considered is the route of administration. This treatment adherence problem can be 
overcome by transdermal drug delivery method which will be advantageous to insure far 
greater patient compliance [20]. Due to improved pharmacokinetic properties, 
transdermal drug delivery is becoming more popular and preferable [21, 22]. Further, the 
transdermal route is beneficial since it avoids one pass through the liver where other 
undesirable biochemical transformations and deactivation take place [23-25]. 
Transdermal studies have used a variety of model skins such as hairless mouse skin, pig 
skin, human cadaver skin and some synthetic membranes [26]. In the present study, shed 
snake skin and excised pig skin are used as a model membranes. The rationale for opting 
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snake skin is that its epidermal layer is considered to have a stratum corneum similar to 
that of human stratum corneum [27]. Its profuse availability, negligible biohazard, its 
easy storage and handling makes it more advantageous [28]. But due to the lack of hair 
follicles, in addition to the shed snake skin, pig skin was also used. The drugs used for the 
study are mentioned in Table 2. All the drug samples selected were analyzed by DEA and 
the data was correlated with the UV studies. The drug throughput and structure were 
confirmed by UV analysis (Absorbance vs. Concentration & maximum peak 
wavelength). The drug purity was set by Differential Scanning Calorimetry. The results 
were interpreted for the analyzed samples. 
Table 2 List of BPD drugs studied 
Drug 
(Trade name) 
CAS No. 
Melting Point 
(°C) 
Mol. Wt. 
(g/mol) 
Structure 
Olanzapine 
(Zyprexa) 
132539-06-1 195 312.44 
 
Risperidone 
(Risperidal) 
106266-06-2 170 410.49 
 
Quetiapine 
Fumarate 
(Seroquel) 
11974-72-2 174 883.11 
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CHAPTER II 
INSTRUMENTS AND METHODS 
 
 
 
2.1 Differential Scanning Calorimetry 
     This is one of the most employed Thermal Analytical techniques for the 
characterization of pharmaceutical solids. It measures the heat flow into and out of a 
sample relative to a reference sample as a function of time and temperature. DSC 
provides test data for a wide range of materials which include polymers, plastics, foods, 
pharmaceuticals, biological samples and more. It measures the following: sample purity 
(Melting points), Heat capacity (cp), Crystallization temperature (Tc), Glass transition 
temperature (Tg), drug stability, and oxidative stability.  
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 Figure 1 Differential Scanning Calorimeter 
   
  
Figure 2 Solid fat index (SFI) pans used for DSC; left- pan, right- lid 
 
2.1.1 Instrument         
     DSC operates over a temperature range of -50 to +300
o
C. It compares differences 
between the heat flow rate of the test sample and known reference materials at a constant 
temperature. DSC plots are obtained as the differential heating rate (in units of watts sec
-
1
, joules sec
-1
 or calories sec
-1
) verses temperature. Calibration parameters, flow rate, 
purge gas are some of the important experimental parameters. Heating rates range from 
1
o
C min
-1
 to 100
o
C min
-1
. 
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2.1.2 Calibration 
     Proper calibration of the instrument is very important to obtain consistent results. 
Following calibration, the characteristic temperatures and the enthalpy associated with a 
phase change can be measured for any sample. High purity calibration standards and 
clean DSC sensors play an important role. Standard reference materials are used to 
calibrate the temperature and energy scales of DSC. Well defined standards and 
calibration procedures should be taken into consideration as crucial factors in comparing 
the results from different instruments. Laboratory-grade chemicals are not suitable for use 
as calibration standards due to the presence of trace amounts of impurities which may 
alter the melting temperature. Calibration should be done as close to the transition 
temperature of interest as possible with the commonly used standards such as indium, tin 
and lead. Standard procedures can be obtained from the American Society for Testing 
Materials (ASTM).  
2.1.3 Sampling 
     A reliable DSC curve can be obtained if there is a good thermal contact of sample 
with the base of the sample pan. The heating a sample to a temperature higher than the 
melting or glass transition temperature makes it possible to obtain a dependable DSC 
curve. Proper choice of experimental conditions leads to a successful experiment. DSC 
uses pans made of aluminum, platinum, stainless steel or silver to minimize the reaction 
with the sample. The experiment can be conducted with an open pan, covered pan or 
sealed pan and the reference pan with similar configuration. The sample size of 2-10mg 
is employed. Samples should be weighed before and after the experiment to observe any 
mass loss upon heating. If powdered samples are used, distribution of the sample evenly 
13 
 
throughout the pan ensures good thermal contact. To obtain accurate quantitative results 
the mass of sample and reference pans should match. 
2.1.4 Procedure 
     Calibration is a basic technique for any instrument in order to obtain accurate results. 
The calibration of this instrument was done based on the Standard Test method for 
temperature calibration of Differential Scanning Calorimetry, adaption ASTM method 
E967-03.sample was first equilibrated to 40
o
C below the melting point and then was 
heated at 3°C min
-1
, in an Aluminum pan (open and closed); 10 mgs sample size. The 
samples used were the APIs and Excipients as powders. As mentioned in ASTM method 
the APIs were placed in a DSC standard aluminum pan except for caffeine, which was 
placed in closed aluminum pan, as it sublimes. Nitrogen gas was supplied in order to 
keep the DSC cell inert. Some of the calibration materials/samples used was Acetanilide, 
Acetophenetidin, Caffeine, and Vanillin. A DSC scan usually provides us the data of the 
following thermal properties- The heat of fusion (∆Hf), melting temperature (Tm) peak 
melt temperature (Tmp), heat of crystallization (∆Hc), crystallization temperature (Tc), 
peak crystallization temperature (Tcp) and glass transition temperature (Tg). The drug 
profile of Acetanilide is illustrated in fig 3. 
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Figure 3 Heat-Cool-Heat cycle of Acetanilide with Tm, Tmp, ∆Hf, Tc, Tcp, ∆Hc 
 
2.2 Dielectric Analysis 
     It measures the electrical properties of a material with the respect of time and 
temperature. DEA measures two fundamental electrical characteristics of a material or 
fluid: Capacitance and Conductance. Unlike DSC, DEA can be used to identify the 
secondary relaxations present in the pharmaceuticals as long as the secondary group has a 
net dipole moment. 
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Figure 4 Dielectric Analyzer (DEA) 
     The capacitive nature of a material is its ability to store electrical charge, and the 
conductive nature is its ability to transfer an electric charge. This component becomes 
more important when the material is heated above the melting temperature to the 
amorphous phase. These electrical properties are related to molecular activity, allowing 
for probing the chemistry, rheology and molecular mobility of drugs and polymers. DEA 
measures three main parameters over a wide range of frequencies (e.g. 0.10 to 10,000 
Hz): 1. Permittivity (e’) is a measure of the alignment of molecular groups (dipoles) in 
the electric field. 2. Loss factor (e’’) is a measure of the energy required to move the 
molecular groups or ions and is proportional to ion conductivity. 3. Tan delta is the ratio 
of the loss factor divided by the permittivity.  
2.2.1Calibrating temperature of Dielectric Analyzer 
     Dielectric analyzers are used to characterize a broad range of materials that possess 
dielectric moments. They can be used over a wide range of temperatures from -100 to 
300°C. One of the desired values to be assigned by the measurements is the temperature 
at which significant changes occur in the properties of test specimen. In order to obtain 
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consistent results from one period of time to another and from one laboratory to another, 
the temperature from the apparatus must be calculated accurately over the temperature 
range of interest. This method covers the temperature range from -100 to 300°C. The 
calibration is performed by observing the melting transition of standard reference 
materials having known transition temperatures within the temperature range of use.  
2.2.2 Instrument 
     The apparatus used is the Dielectric Analyzer (DEA) TA instrument (TAI) 2970. The 
following parameters should be taken into consideration: Sensors, impart the alternating 
electric field and measure the induced current and phasing in the sample specimen. These 
sensors may be either parallel plate or a single plate containing a series of interdigitated 
electrodes. Single surface interdigitated electrodes are used in this experiment, the 
temperature Programmer and Furnace set the heating rate and operating temperatures 
below ambient temperatures. Cooling may be by a mechanical refrigerator or other 
coolant such as liquid nitrogen. Specimen Atmosphere Control System, capable of 
supplying inert gas, usually nitrogen with a selectable flow rate of 50 mL min
-1
. The 
dielectric thermal curve consisting of permittivity on the Y axis (ordinate) and 
temperature on the X axis (abscissa) was set for the calibration material for e.g. 
Acetanilide, Vanillin, and Acetophenetidin. 
     Small sample sizes are used for the analysis. The mixing or stirring of samples prior to 
the analysis was recommended. Any mechanical or thermal treatment, such as grinding or 
sieving if applied to the sample before analysis was recorded. The sample must cover the 
electrode array completely. 
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2.2.3 Procedure 
     Load the calibration material into the DEA instrument. Set the initial temperature of 
the apparatus to a value of about 30°C below the estimated transition temperature of the 
calibration material. The sample was analyzed at a heating rate of 5°C min⁻¹ in flowing 
nitrogen at 50 mL min⁻¹ to a temperature above 20°C above the estimated transition 
temperature of the calibration material. Initiate the measurement of permittivity over 
frequencies from 0.1Hz to 1000 Hz and single frequency 1000 Hz to record permittivity 
measurement on a linear scale, as a function of temperature. Remove the residue material 
and clean the electrode after the experiment.  
2.3 Thermal Gravimetric Analysis (TGA) 
     The primary purpose of everyday routine TGA experiments is to measure moisture 
content, residual solvent, and polymerization of materials like phenolics that evolve 
reaction products. 
2.3.1 Instrument 
     The heart of the TGA is the furnace and the area surrounding it. Regular heating of 
furnace and the sample holder up to 800°C in air for 10-15 minutes should be done to 
keep them clean from organic residues. The instrumental baseline should be checked 
occasionally, especially after running a furnace cleaning procedure and where very small 
weight losses are being recorded. When performing TGA runs, the following 
experimental conditions should be carefully selected.      
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2.3.2 Sampling and Procedure 
     Before loading the sample into the TGA instruments, it has to be weighed into TGA 
pans. Platinum, aluminum (sealed and open) are usually the commercially available TGA 
pans. Platinum pans are used to analyze polymers as they can withstand high 
temperatures (up to 800°C). Aluminum pans can be used for the measurements that leave 
a stable residue. The sample should be weighed on an electronic microbalance to at least 
±0.01% accuracy. Usually minimum sample weights are used to decrease the thermal lag 
and the internal thermal resistance of the sample. But sometimes larger sample weights 
are used in order to increase the sensitivity of the measurement. After the sample has 
been prepared, it is weighed into the TGA pan, usually at room temperature. A variety of 
purge gas options are available. An inert atmosphere, usually high purity dry nitrogen, 
should be used when it is important to avoid oxidative processes. If the source of the 
purge gas is compressed air it is important to use a filter to remove any pump oil. It may 
be useful to purge the TGA furnace with a gas, usually air or nitrogen that contains a 
controlled amount of moisture. The flow rate of the purge gas is important, and it should 
be set as suggested by the manufacturer. Initially the sample pan weight is tared to zero. 
After this, the sample is carefully loaded into the pan and the experiment is set to run. 
The sample is heated at a rate of 10°C min⁻¹ with purging of nitrogen at a flow rate of 50 
ml min⁻¹. Then the data is analyzed using TA software. 
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CHAPTER III 
Dielectric Analysis Enhances Characterization of Pharmaceutical Excipients. 
Hareesha Reddy Venumuddala 
(Manuscript submitted for publication and is under review) 
(Journal of Thermal Analysis Calorimetry) 
  
 
3.1 Abstract 
     Millions of dollars are expended annually on pharmaceutical testing to qualify 
excipients for fully formulated drugs, medicines, and active ingredients. To understand 
the action of the excipients in the human body at body temperature, 37°C the study of 
their individual and interactive properties is desirable. Dielectric Thermal Analysis 
(DEA), Differential Scanning Calorimetry (DSC) and Thermal Gravimetric Analysis 
(TG) methods were employed to screen the most widely used drug excipients. In this 
study the following chemicals were examined by DEA: calcium phosphate, cotton seed 
oil, croscarmellose, gelatin, mannitol, peanut oil, polyethylene glycol, pioneer sugar, 
plasdone, sodium alginate, sodium lauryl sulfate, sodium starch glycolate, sodium  
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stearate, a sorbitol solution, canola oil, anhydrous lactose, and benzoic acid. The 
comparison of DSC and DEA thermal curves for each excipient indicates that major 
endothermic events, e.g. volatilization or melting of the excipient or a drug, are 
delineated by fundamental DEA properties, with an exponential rise in permittivity and 
dielectric loss factor. The focus of this research is to study the ―thermal event‖ response 
from the DEA, that is, the electrical conductivity (loss factor*frequency*constant), 
permittivity and tan delta (loss factor/permittivity) vs. frequency. 
Key Words:  Excipient, DSC, DEA, TGA, Polymorph.  
3.2 Introduction 
     Preformulation studies are used for the characterization of drug substances and 
excipients
 
[1]. There is an ongoing need for technical information that describes physical 
and chemical properties of drugs and excipients in the development of formulations and 
manufacturing processes
 
[2]. Preformulation studies often include, crystal size and shape; 
polymorphism; drug permeability; pH-solubility profiles; pH-stability profiles; and 
screening for suitable excipients.  
     Thermal analysis and Microcalorimetry are key tools for purity evaluations, thermal 
and oxidative stability determination, and drug-excipient compatibility studies. Thermal 
analytical techniques are used to characterize the behavior of pharmaceutical samples as a 
function of temperature or time [3, 4]. These methods include DSC, DEA, and TGA [5, 
6]. DSC and TGA are continually used to study and characterize potential drug-drug, 
drug-excipient interactions using thermal analysis [7, 8]. 
     DEA, employing an interdigitated array of electrodes, is a new innovative physical-
analytical method in evaluating real world excipient interactions and possibly predicting 
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performance. DEA measures two fundamental electrical characteristics of a material or 
fluid, capacitance and conductance as a function of time, temperature, and frequency. The 
capacitive nature is the ability of the material to store an electrical charge and dominates 
the electrical response at low temperatures. The conductive is the ability to transfer an 
electrical charge and this component becomes important when the material is heated 
above the melting temperature.  
     DEA measures three main quantities over a wide range of high frequency: 
permittivity, loss factor, and tan delta.  Permittivity (dielectric constant at high frequency) 
is a measure of the alignment of the molecular groups to the electric field. Loss factor is a 
measure of the energy required to move the molecular groups or ions and is proportional 
to ion conductivity (loss factor*frequency*constant and the energy to align dipoles). 
Moreover, ion conductivity becomes increasingly sensitive when the material becomes 
fluid. Finally, tan delta is the ratio of the loss factor to permittivity. Drug degradation and 
stability are revealed by TGA studies
 
[9].  
     Thus, DSC, TGA and DEA, were applied to screen the model excipients, which all 
have specific purposes in the pharmaceutical industry. The assets of these techniques are 
that one can evaluate critical properties based on very small amounts of chemical in a 
very short time
2
. Benzoic acid also known as flowers of benzoin is commonly used as an 
antiseptic in cough medications [10, 11]. Mannitol is a naturally occurring sugar alcohol 
that is non-hygroscopic and is typically utilized in food applications and therapeutically 
to decrease cellular edema and increase the urinary output [11]. Anhydrous lactose is 
milk sugar that serves as a dilutent, filler, and bulking agent. It is also provides free flow 
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ability and avoids segregation in capsule filling [10-13]. Calcium phosphate is binder, 
filler and sometimes an antacid [11].  
     Polymorphism is the ability of a compound to crystallize in more than one distinct 
crystal structure. Polymorphs usually show different physiochemical behavior in 
properties of pharmacological interest such as: density, hardness, hygroscopic tendency, 
solubility velocity, or thermal stability [12]. One polymorph can be converted into 
another under certain circumstances and can be characterized by DSC, TGA, and other 
combined techniques. 
3.3 Experimental 
3.3.1 Materials Used 
     All excipients, except benzoic acid were received from the University of Toledo, 
College of Pharmacy. The original source and condition of all the samples are in Table 3. 
Table 3 List of Excipients 
Excipient CAS Phase 
Melting Point 
(
o
C) 
Source 
Functional 
Category 
Benzoic 
Acid 
65-85-0 Solid 122 
Fisher Scientific  
Company 
Preservative 
Mannitol 69-65-8 Solid 165 Atlas Chem. 
Sweetening 
agent 
Anhydrous 
Lactose 
63-42-3 Solid 223 
Eastman 
Organic 
Chemical 
Diluent, 
Filler 
Calcium 
Phosphate 
7756-87-4 Solid Decomp*>100 
Amend Drug 
Chemicals 
Buffer, 
Glidant, 
Diluent 
*Decomp = Decomposition 
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3.3.2 Methods 
     The TA Instruments (TAI) Dielectric Analyzer 2970 was used for dielectric analysis 
of the samples over a wide range of frequencies from 0.1 to 1000 Hz and temperatures 
from –50 to 300oC. Other parameters included a heating rate of 10oC min-1, nitrogen gas 
purge at a flow rate of 50mL min
-1
, and liquid nitrogen cooling when necessary. The 
single surface gold ceramic interdigitated sensors were utilized. A Sample size of 10-
20mg of either solid or liquid sample was used to cover the plated sensor with a thin 
layer. DEA calibrated with acetanilide with a Tmp 115
 o
C (DSC) and Tm (DEA) 114
 o
C. 
     The TAI DSC 2920 was used to verify heat flow properties as a function of 
temperature. The heating rate was 10
o
C min
-1
 from –50 to 255oC with nitrogen gas purge 
at 50mL min
-1
. Sample size was between 4 and 6mg.   
     The TAI TGA 2950 was also used to verify mass loss properties as a function of 
temperature. The heating range was 10
o
C min
-1
 from ambient to 500
o
C with nitrogen gas 
purge at 50mL min
-1
 and nitrogen gas balance purge at 40mL min
-1
. Sample size was 
between 7 and 12mg. 
3.4 Results and Discussion 
     Tan delta, permittivity, and ion conductivity curves at 0.1, 10, and 100Hz respectively, 
were specifically interpreted for evaluation. The 0.1Hz tan delta is very sensitive to 
molecular relaxations and changes in chemical behavior at the surface of the electrode. 
The DEA sensor evaluates chemicals within 300µ from the electrode surface. This is 
based on the envelope of chemicals being evaluated that is 3 times the distance between 
the interdigitated electrodes or 100 microns.   
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     The 10Hz permittivity was selected based on its repeatability and correlation with 
other permittivity measurements. Permittivity is very sensitive to chemistry variations, 
that is, molecular chemical changes at the surface of the electrode and not related to bulk 
changes in the chemicals. The 100Hz conductivity (also a near surface measurement) was 
selected based on its repeatability and correlation with other real world conductivity 
measurements.  This is based on preparing non-aqueous solutions of known conductivity 
and measuring it by several methods including the DEA. The 100Hz was the most 
reliable and comparable with real world conductivity values.  
Benzoic Acid 
     Benzoic acid is considered as a calibrant in this study. In the overlay of the DSC and 
100Hz ion conductivity DEA curve (Fig. 5), a strong endothermic peak is evident at 
124
o
C for the DSC and corresponds to a peak on the DEA at 118
o
C. The finding is 
supported by the known standard melting point of benzoic acid at 122
o
C
 
[11]. The 
endothermic DSC peak and the rise of slope in the DEA curve following their respective 
melting point peaks are probably due to the sublimation stages of the material and the 
TGA curve (Fig. 6) indicates complete weight loss due to sublimation and is reached 
around 160
o
C. The DSC gave sharp melting peaks while the DEA gave broad diffuse 
peaks in the same general temperature range. Therefore, the DEA is less sensitive than 
the DSC to melting, but is more sensitive to polar-dipole constituents.  However, the 
DEA is more sensitive to overall events. 
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Figure 5 Benzoic acid DSC and 100Hz Ion Conductivity DEA 
 
Figure 6 TGA of Benzoic acid 
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Mannitol 
     The mannitol overlay of the DSC, TGA, and the 100Hz ion conductivity DEA (Fig 7), 
reveals a significant endothermic DSC peak at 168
o
C and the DEA confirms this with its 
peak at 167
o
C. The peaks represent the melting point of the sample as no weight loss is 
recorded from the TGA at the equivalent temperature. The ionic conductivity becomes 
increasingly sensitive when the material becomes fluid and amorphous. The standard 
melting temperature of mannitol is 164 to168
o
C depending on the type of mannitol [11, 
14]. The resulting DEA/DSC temperature is accurate when compared to the standards; 
however, polymorphism may have some effect on this property. 
 
Figure 7 Mannitol TGA, DSC and 100Hz DEA Ionic Conductivity 
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     Next, from a magnified image the DEA curve (Fig 9), a second peak occurs at 1
o
C 
that has no corresponding DSC peak. An obvious advantage of the DEA over the DSC is 
now evident. The origin of this DEA peak is most likely from beta transitions or water 
fusion. The transitions involve the rotation of short-chain OH side groups on the mannitol 
structure and therefore, occur below. 
 
 
 
 
 
 
 
 
Figure 9 Mannitol DSC and 100Hz DEA Ionic conductivity 
Figure 8 Mannitol structure 
28 
 
Anhydrous Lactose  
     In the overlay of the DSC, TGA, and 10Hz permittivity DEA (Fig. 10), a major 
endothermic DSC peak at 235
o
C is exhibited and the DEA curve is also increasing to 
reach a peak around 235
o
C. Both the DSC and DEA suggest that 235
o
C is the melting 
point and the decomposition of the sample begins shortly thereafter, as supported by the 
TGA. The standard melting point is actually 223
o
C and again, the temperature difference 
is most likely due to polymorph behavior
10
. In addition, the DEA exhibits a beta 
transition peak with the OH side chains on the molecule at -7
o
C and the DSC has no 
indication of any activity, similar to mannitol. 
 
 
Figure 10 Anhydrous Lactose DSC, TGA and 10Hz Permittivity DEA 
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Calcium Phosphate 
     The overlay of DSC, TGA, and 10Hz ion conductivity DEA (Fig. 11) indicates a DSC 
exothermic peak at 13
o
C and corresponds to the DEA peak at roughly 11
o
C.  The cause is 
likely due to the crystallization of the sample. 
     The TGA curve shows about twenty percent weight loss of the sample over a span of 
roughly three hundred degrees, from 100 to 400
o
C. The standard melting point of pure 
calcium phosphate is over 1000
o
C. Thus; the weight loss is probably not due to properties 
of calcium phosphate. Consequently, impurities in the sample are the likely cause of the 
activity. The Therm Ex-GC/MS was again used for the sample. Results identify two main 
compounds in the first partition between 25 and 150
o
C:  propanal, 2-oxo- (C3H4O2), 
which has a boiling point of 72
o
C; and 1-methoxy-2-propyl acetate (C6H12O3). The 
decomposition of a combination of these two is probably responsible for the DSC 
endothermic peak at 144
o
C, which corresponds to the DEA peak at 143
o
C and the first 
weight loss from the TG around 113
o
C. The second partition from 150 to 300
o
C shows 1-
methoxy-2-proyl (C6H12O3) and is probably the remainder of the compound from the 
earlier decomposition. 
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Figure 11 Calcium Phosphate DSC, TGA and 100Hz Ionic conductivity 
3.5 Conclusions 
     As far as the excipients are concerned, when comparing the complexity of the analysis 
results of the liquid versus solid, the liquid samples are more difficult to interpret due to 
the fact that liquid samples themselves are more complicated. Low temperature properties 
of excipients reveal endothermic and conductivity changes as a result of various 
transitions. Higher temperature properties designate the relative thermal stability or a 
property change as a function of temperature. The DEA is more sensitive to polar versus 
non-polar chemicals, overall thermal events, and to polar-dipole constituents; however, 
the DEA is less sensitive than the DSC to melting. Even so, the DEA serves a valuable 
tool when it comes to analyzing the thermal properties of excipients used for 
pharmaceutical purposes.  Nevertheless, using a variety of instruments to complement the 
DEA, DSC, TGA are necessary to assist in interpreting accumulated data and to ensure 
detailed analysis.   
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3.6 Further Studies 
     Future work includes more research and testing of excipients to determine the exact 
origin of certain indeterminate peaks for selected samples, interpreting the data of the 
remaining excipients, and applying excipients data to assist in the development or 
modification of pharmaceutical drugs.  We also want to blend excipients into a two or 
three component system for analysis to collect data over a wide concentration range, thus 
aiding in the development of a computer simulation model that could predict the 
interactive behavior of the forty most prominent excipients. 
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CHAPTER – IV 
Characterization and Evaluation of Atypical Antipsychotics for Transdermal 
Delivery by Dielectric Analysis and Ultraviolet-Visible Spectroscopy 
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4.1 Abstract 
Atypical antipsychotics are emerging as effective drugs for the treatment of Bipolar 
Disorder (BPD), a common and recurrent mood disorder. Historically, this class of drugs 
has been specifically used to treat Schizophrenia.  More recently, their mood stabilizing 
properties and reduced extra pyramidal effects have made them treatments of choice for 
BPD consumers. Studying the transport properties of these drugs through a transdermal 
route may pave the way for a novel transdermal drug delivery method. This will aid BPD 
patients to receive their dosage in a timely manner and improve patient compliance. In 
this study, Dielectric Analysis (DEA) is used to characterize and evaluate the transport 
properties of the selected drugs (Olanzapine, Risperidone, and Quetiapine Fumarate). 
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DEA implements drug delivery employing an AC frequency, modulating drugs of a wide 
molecular weight range (e.g. 300 to 30,000 Daltons) with an interdigitated electrode  
system. In this analysis, the drugs were studied using an animal model (shed snake skin). 
There is a specific range of critical frequencies discovered for each drug associated with 
active drug transport. Drug transport is measured by observed increases in conductivity 
of the shed snake skin and is confirmed with drug throughput measured by UV 
spectroscopy.  
Key Words: atypical antipsychotics; bipolar disorder; dielectric analysis; ultraviolet-
visible spectroscopy; differential scanning Calorimetry. 
4.2 Introduction 
       Bipolar disorder (BPD) is a widespread chronic disorder with recurrent 
episodes of mania and depression [1]. It accounts for 25% of all mental disorders. For 
many years, the conventional mood stabilizers such as lithium (as carbonate and citrate) 
and antidepressants have been used as a first choice of medication for the treatment of 
BPD patients before the evolution of newer medications [2-4]. Due to their long-term 
side effects, recently a new class of antipsychotic drugs, the atypical antipsychotics, has 
become effective with fewer side effects and better mood stabilizing properties [5]. It is 
very important for a bipolar disorder patient to take medications in a timely manner. 
Untimely discontinuation of the medications is the major complication to positive 
outcomes in individual bipolar disorder patients. Treatment adherence is a very important 
aspect to be considered and it is affected by various factors like age, gender, medication 
side effects and other environmental factors [1, 6 and 7]. Another important factor to be 
considered is the route of administration. This treatment adherence problem can be 
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overcome by transdermal drug delivery method which has been advantageous to insure 
far greater patient compliance [8]. Due to improved pharmacokinetic properties, 
transdermal drug delivery is becoming more popular and preferable [9, 10]. Further, the 
transdermal route is beneficial since it avoids one pass through the liver where other 
undesirable biochemical transformations and deactivation take place [11-13]. 
Transdermal studies have used a variety of model skins such as hairless mouse skin, pig 
skin, human cadaver skin and some synthetic membranes [14]. In the present study, shed 
snake skin is used as a model membrane. The rationale for opting snake skin is that its 
epidermal layer is considered to have a stratum corneum similar to that of human stratum 
corneum [15]. Its profuse availability, negligible biohazard, its easy storage and handling 
makes it more advantageous [16]. 
      Most transdermal drug delivery platforms rely on passive diffusion. Commercial 
transdermal patches have also been developed to deliver the drugs using an electric field. 
The prime objective of this research is to achieve a controlled release delivery FDA-
approved BPD drugs into and through the skin using Dielectric Analysis (DEA). This 
thermal technology uses a series of optimum AC signals to transfer the drug through the 
skin at a controlled rate. The drug throughput was confirmed by UV analysis. The drug 
purity was set by Differential Scanning Calorimetry. 
      Thermal analytical techniques have been used in this study to reveal the transport 
properties of the selected drugs. Dielectric Analysis (DEA) is known to be a versatile tool 
for material characterization. It is used to evaluate the electrical properties of a wide 
range of materials, drugs and pharmaceuticals available in different forms. It is used over 
a wide range of frequencies, from 0.1Hz to 100,000Hz and temperatures from 50 to 
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250
o
C and measures three main properties: permittivity, loss factor and tan delta. 
Permittivity (dielectric constant at high frequency) is a measure of the alignment of the 
molecular groups to the electric field. Loss factor is a measure of the energy required to 
move the molecular groups or ions and is proportional to ion conductivity (loss 
factor*frequency*constant (2п) and the energy to align dipoles). Moreover, ion 
conductivity becomes increasingly sensitive when the material becomes fluid. Finally, tan 
delta is the ratio of the loss factor to permittivity. All the drug samples selected were 
analyzed by DEA and the data was correlated with the UV studies. The results were 
interpreted for the analyzed samples. 
     The antipsychotic drugs used in this study are Olanzapine, Risperidone, and 
Quetiapine Fumarate. Olanzapine belongs to the class of thienobenzodiazepine and is 
chemically referred to as 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thienol [2, 3-b] [1, 5] 
benzodiazepine [17]. It is the most widely studied drug of this class. It has significant 
evidence of efficacy in the treatment of manic phase as well as depressive phase of 
Bipolar Disorder [18]. It is a yellow crystalline solid and is taken through an oral route of 
administration [19]. It is an FDA approved drug in the U.S and is approved for use in 
Europe [20]. Olanzapine is also effective at delaying or preventing relapse during long-
term maintenance therapy in treatment responders, and is currently the only atypical 
antipsychotic approved for this indication. Risperidone is a white powder which is 
practically insoluble in water. It belongs to the chemical class of benzisoxazole 
derivatives which is chemically designated as 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)1-
piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one [21]. It 
is usually administered as tablets, liquids, injection and orodispersible tablets.  Quetiapine 
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Fumarate which is chemically designated as 2-[2-(4-dibenzo [b, f] [1, 4] thiazepin-11-yl-
1-piperazinyl) ethoxy]-ethanol fumarate (2:1) (salt) and belongs to the class of 
dibenzothiazepines. The FDA has approved Quetiapine monotherapy for the acute 
treatment of depressive episodes associated with bipolar disorder and as maintenance 
treatment of bipolar disorder as an adjunct to lithium or divalproex. It is an off-white 
crystalline powder, slightly soluble in water [22].  
4.3 Materials and Methods 
4.3.1 Drugs 
All the drug samples were ordered from Haorui Pharma-Chem Inc.100 Menlo Park Dr., 
Suite 316, Edison, NJ 08837, USA. 
Table 4 List of drugs studies 
Drug 
(Trade 
name) 
CAS No. 
Melting 
Point (°C) 
Mol. Wt. 
(g/mol) 
Structure 
Olanzapine 
(Zyprexa) 
132539-06-1 195 312.44 
 
Risperidone 
(Risperidal) 
106266-06-2 170 410.49 
 
Quetiapine 
Fumarate 
(Seroquel) 
11974-72-2 174 883.11 
 
 
4.3.2 Skin Membranes 
     The shed skin of a Cuban Boa (Epicrates angulifer), a black snake, is used in this 
permeation study. It mainly comprises of two portions: the core and the boundary. The 
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core thickness is 20 μ and the boundary is 150 μ thick (Fig. 12). The latter portion is 
densely porous through which the drug diffuses. The skin is always sealed in plastic bags 
and refrigerated at temperature of -20°C.          
 
Figure 12 Shed skin of Boa   
4.3.3 Experimental Methods 
     The TAI DSC 2920 was used to verify drug purity and heat flow properties as a 
function of temperature. DSC scans were run over a temperature range of –50 to 255oC 
with nitrogen as purge gas at 50mL min
-1
. Sample size was between 2 to 6mg.  DSC uses 
pans made of aluminum, platinum, stainless steel or silver to minimize the reaction with 
the sample. The experiment can be conducted with an open pan, covered pan or sealed 
pan and the reference pan with similar configuration. In this study, commercial solid fat 
index (SFI) aluminum pans (Fig. 13) were used and the experiment was conducted with 
an open pan. The samples were weighed and loaded into the pans. The sample is 
subjected to a Heat-Cool-Heat (HCH) cycle. We started at 28
o
C and heated to 40
o
C 
above the melt temp, i.e. the extrapolated onset temperature and cooled to 40
o
C below the 
melt temperature at a rate of 10
o
C min
-
¹. The data is analyzed using TAI Universal 
Analysis software. 
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Figure 13 Solid fat index (SFI) pans 
     The TA Instruments (TAI) Dielectric Analyzer 2970 was used for dielectric analysis 
of the samples over a wide range of frequencies from 0.1 to 100,000 Hz and temperatures 
from –50 to 300oC. Other parameters of the instrument included: the heating rate, purge 
gas, and liquid nitrogen cooling when necessary. The single surface gold ceramic 
interdigitated sensors were used (Fig. 14). A sample size of 2 to 6mg of each drug was 
evaluated. The sample was properly weighed and the shed snake skin is cut according to 
the size of the sensor. The skin was soaked in pH buffer 7.4 for 10 to 12hrs before the 
experiment. The weighed sample is then evenly loaded on to the top portion of the skin 
which is carefully placed on the electrode (Fig. 15). Then the sample is subjected to 
heating at a rate of 10°C min
-1
 up to 37
o
C and then kept isothermal for 40 min at that 
temperature with nitrogen as a purge gas at a flow rate of 50mL min
-1
. The frequency 
range was selected from 0.1 to 30,000 Hz. The electrical response of the sample is 
recorded and the samples were analyzed. After each experiment, the skin is safely 
discarded and the electrode is soaked in an appropriate solvent for the drug (Olanzapine 
and Quetiapine Fumarate in Methanol and Risperidone in 0.1M H2SO4) for an hour. The 
residue in solution is then collected in a glass vial for UV analysis.  For each drug, two 
separate DEA studies were conducted and two separate residue samples were collected 
from those studies.  Similarly, two negative controls were run in the DEA apparatus with 
40 
 
no applied electric field and these samples were also collected using the same method 
described above.  
 
Figure 14 Single surface gold ceramic sensor                                                         
            
Figure 15 Drug on top of snake skin                                                                                                                                        
     The Cary 50 B10 UV-Visible spectrophotometer is used to evaluate the concentration 
of the drug throughput. For this study stock solutions of known drug concentration were 
prepared   using approximately 2 to 6 mg of each drug in a drug soluble solvent. A 
calibration curve was developed from the above stock solutions with measured 
absorbance vs. concentration of each drug at a particular wavelength (Olanzapine at 363 
nm, Risperidone at 280 nm and Quetiapine Fumarate at 303 nm). Two test samples and 
two control samples of unknown drug concentration of each drug collected in the vials 
were screened by UV spectroscopy. These samples were scanned and the absorbencies 
measured were fit into the standard calibration curve. Thus the unknown concentration of 
the sample is interpolated from the calibration curve or can be derived from the Beer-
Lambert law and is compared with the negative control sample. 
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4.4 Results and Discussion 
4.4.1 DSC Evaluation 
     DSC revealed the purity of the three drugs tested in our study. In comparison of the 
melt temperature (Tm) measured to the literature value, the relative purity can be 
ascertained. The three drugs in this study, Olanzapine, Risperidone and Quetiapine 
Fumarate were observed to have melting temperatures same as that of literature with the 
correlation co-efficient of 0.98. The DSC protocol also aids in defining the ability of the 
crystalline solid to recrystallize or remain amorphous and produce a glass transition 
temperature. The DSC profile of Risperidone shown below (Fig. 16) illustrates the Heat-
Cool-Heat cycle in which it happens to recrystallize upon cooling and melting upon 
reheating which confirms it to be a crystalline material. Whereas, Olanzapine and 
Quetiapine Fumarate do not recrystallize upon cooling, thus exhibiting their amorphicity. 
The heat of fusion (∆Hf), melting temperature (Tm) peak melt temperature (Tmp), heat of 
crystallization (∆Hc), crystallization temperature (Tc), peak crystallization temperature 
(Tcp) and glass transition temperature (Tg) were determined for all the three drugs and 
listed in Table 5. The drugs used in this study are probably >99%w pure. 
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Figure 16 DSC profile of Risperidone with melting temperature 
 
Table 5 Thermal properties of drugs by DSC 
Cycle Values Olanzapine Risperidone Quetiapine Fumarate 
 Literature Value 195 170 174 
Heat1 Tm (
o
C) 194 170 174 
 Tmp (
o
C) 196 172 176 
 ∆Hf 107 90 122 
Cool Tc (
o
C) - 138 - 
 Tcp (
o
C) - 133 - 
 ∆Hc - 73 - 
Heat2 Tm (
o
C) - 168 - 
 Tmp (
o
C) - 171 - 
 Tg (
o
C) 73 - 54 
 ∆Hf - 80 - 
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4.4.2 Dielectric Analysis 
     From the dielectric profiles of each drug obtained, the log conductivity (pScm
-1
) 
values were plotted against log frequency (Hz). In this Debye plot, it is observed that the 
three drugs exhibited a marked change in the slope at about a frequency of 100 Hz. This 
frequency is called the critical frequency and this change is interpreted as a measure of 
the drug throughput using the shed snake skin as the animal model. The Debye plot of 
Olanzapine is illustrated in Fig. 17, Fig. 18 and Fig. 19 indicates the slopes before and 
after the critical frequency. Olanzapine and Risperidone have an increased percentage of 
rates of change of log conductivity vs. log frequency which is interpreted as a positive 
sign of drug transport (see Table 6). 
 
Figure 17 Dielectric profile of Olanzapine, isothermal at 37°C for 40 min 
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Figure 18 Olanzapine DEA profile before change 
 
 
Figure 19 Olanzapine DEA profile after change 
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Table 6 Analysis of DEA data to rank drug transport for the three drugs in shed snake 
skin 
Drugs Slope 1 Slope 2 
Ratio 
(S2/S1) 
% Increase of 
S2 vs. S1 
Olanzapine 0.500 0.827 1.70 70 
Risperidone 0.681 0.988 1.45 45 
Quetiapine Fumarate 0.732 0.817 1.12 12 
Note: S1-Slope 1, S2-Slope2; S2 vs. S1 = Delta log conductivity/delta log frequency 
4.4.3 Spectroscopic evidence of drug delivery through the animal model membrane: 
     Monitoring the transport of the drug through the animal membrane was accomplished 
by UV Analysis. The calibration curve of Olanzapine is illustrated below in the Fig. 20. 
The three drugs scanned before measuring absorbencies confirmed peaks at about same 
wavelengths as that of the original drug (Olanzapine at 362 nm, Risperidone at 282 nm 
and Quetiapine Fumarate at 303 nm). The transport of drugs through the shed snake skin 
membrane illustrated a throughput of apparently 12 to 70% with an average of 42% (seen 
above in Table 6). The relationship between the end-point ionic conductivity and the 
measured concentration of membrane throughput by the drug was a cause and effect 
relationship, i.e., the conductivity (52.3 ±5.3 pS/cm or ±10%) at 35 min was related to the 
average drug transport (0.114 ±0.020 mg/mL or ±17%). Table 7 summarizes the results, 
with the two studies run for each drug designated with subscript 1 and subscript 2. 
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Figure 20 Olanzapine calibration curve 
Table 7 End-point conductivity and throughput 
Drug 
Sample 
(Abs.) 
Control 
(Abs.) 
Difference 
Average of 
Difference 
End point 
conductivity 
Olanzapine1 
Olanzapine2 
0.0935 
0.1048 
0.0026 
0.0089 
0.0909 
0.0959 
0.093 54.3 
Risperidone1 
Risperidone2 
0.0898 
0.2301 
0.0277 
0.0245 
0.0621 
0.2056 
0.134 
46.2 
 
Quetiapine F.1 
Quetiapine F.2 
0.0667 
0.2031 
0.0155 
0.1950 
0.0512 
0.1840 
0.117 
56.3 
 
 Average 
 
   0.114 52.3 
Standard 
Deviation 
   0.020 5.34 
Ratio    17% 10% 
End point conductivity of the drugs is 30,000 Hz. 
Olanzapine Calibration 
y = 780.9x - 0.001
R² = 0.999
0
0.1
0.2
0.3
0.4
0.5
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0 0.0002 0.0004 0.0006 0.0008 0.001 0.0012
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4.5 Conclusion  
     This study produced varying results of drug through put across a bio membrane. It is 
our opinion that a positive slope change in the log conductivity vs. log frequency curve 
implies good drug transport. This fact has been substantiated by determining the drug 
throughput of 12 to 70% by UV spectroscopy on the delivery side of the membrane. 
     UV analysis of the drug samples compared against the control samples yielded 
positive results of drug delivery. A calibration curve prepared from the stock solutions of 
each drug resulted in an R
2
 value of about 0.99. The test samples analyzed were found to 
contain the drug delivered through the skin. The enhanced slope above the critical 
frequency is evidence that this protocol for drug transport is effective. The variation in 
the mg mL
-1
 in the observed throughput is ±17% and has a cause and effect relationship 
with the conductivity.  Future studies will replicate DEA controlled release in a pig skin 
animal model. 
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CHAPTER V 
TRANSDERMAL DELIVERY: CHARACTERIZATION OF BIPOLAR 
DISORDER DRUGS AND STUDY OF THEIR TRANSPORT THROUGH  
BIOMEMBRANES 
 
 
5.1 Introduction 
     All the drug samples studied were ordered from Haorui Pharma-Chem Inc.100 Menlo 
Park Dr., Suite 316, Edison, NJ 08837, USA (see Table 8). 
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Table 8 BPD drugs studied 
Drug 
(Trade name) 
CAS No. 
Melting 
Point (°C) 
Mol. Wt. 
(g/mol) 
Structure 
Olanzapine 
(Zyprexa) 
132539-06-1 195 312.44 
 
Risperidone 
(Risperidal) 
106266-06-2 170 410.49 
 
Quetiapine 
Fumarate 
(Seroquel) 
11974-72-2 174 883.11 
 
 
Olanzapine 
     Olanzapine belongs to the class of thienobenzodiazepine and is chemically referred to 
as 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thienol [2, 3-b] [1, 5] benzodiazepine (29).It 
is a yellow crystalline solid and is usually taken through an oral route of administration 
only.  
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Figure 21 Chemical structure of Olanzapine 
     It is the widely studied drug of this class. It has significant evidence of efficacy in the 
treatment of manic phase as well as depressive phase of Bipolar Disorder from the earlier 
studies (30). It is an FDA approved drug in U.S and Europe (31). Olanzapine is also 
effective at delaying or preventing relapse during long-term maintenance therapy in 
treatment responders, and is currently the only atypical antipsychotic approved for this 
indication. This is a faster oral disintegrating drug than others. Olanzapine is believed to 
exert its antimanic and antipsychotic effects predominantly by binding to and blocking 
dopamine D2 and serotonin (5-hydroxytryptamine) 5-HT2A receptors though the exact 
mechanism of the disorder is not known (32). 
Risperidone 
     Risperidone belongs to the chemical class of benzisoxazole derivatives which is 
chemically designated as 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl) 1-piperidinyl] ethyl]-
6, 7, 8, 9-tetrahydro-2-methyl-4H-pyrido [1, 2-a] pyrimidin-4-one (33, 34). It is a white 
powder which is practically insoluble in water. 
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Figure 22 Chemical structure of Risperidone 
     Risperidone is usually used to help treat illnesses or conditions such as psychosis, 
schizophrenia, mania and hypomania. The main pharmacological activities of risperidone 
include serotonin 5-HT2 receptor blockade and dopamine D2 antagonism (Megens et al, 
1994) (35). It is usually administered as Tablets, Liquid, Injection, Orodispersible tablets 
(36). At dosages £8 mg/day, risperidone is generally associated with a lower risk of extra 
pyramidal symptoms than conventional antipsychotics and may have a more favorable 
effect on cognitive functioning of the brain. 
Quetiapine Fumarate 
     Quetiapine Fumarate which is chemically designated as 2-[2-(4-dibenzo [b, f] [1, 4] 
thiazepin-11-yl-1-piperazinyl) ethoxy]-ethanol fumarate (2:1) (salt) which belongs to the 
class of dibenzothiazepines. It is an off-white crystalline powder, slightly soluble in water 
(37). 
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Figure 23 Chemical structure of Quetiapine Fumarate 
     It is an atypical antipsychotic agent widely used as a first line drug for the treatment of 
schizophrenia. Moreover, the FDA has approved quetiapine monotherapy for the acute 
treatment of depressive episodes associated with bipolar disorder and as maintenance 
treatment of bipolar disorder as an adjunct to lithium or divalproex. 
Materials Used 
     The shed snake skin and excised pig skin are used as models of human skin. The shed 
skin of a Cuban Boa (Epicrates angulifer), a black snake, is used in this permeation 
study. It mainly comprises of two portions: the core and the boundary. The core thickness 
is 20μ and the boundary is 150 μ thick (Fig 24). The latter portion is densely porous 
through which the drug diffuses.  
 
Figure 24 Shed snake skin    
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     Pig skin samples with thickness ranging from 0.1cm to 0.2cm were obtained from 
adult Yucatan pigs. The skin is always sealed in plastic bags and refrigerated at 
temperature of -20°C. The surface areas of both the skins were cut according to the size 
of the electrodes.     
5.2 Procedure 
     The TAI DSC 2920 was used to verify drug purity and heat flow properties as a 
function of temperature. DSC scans were run over a temperature range of –50 to 255oC 
with nitrogen as purge gas at 50mL min
-1
. Sample size was between 2 to 6mg.  DSC uses 
pans made of aluminum, platinum, stainless steel or silver to minimize the reaction with 
the sample. The experiment can be conducted with an open pan, covered pan or sealed 
pan and the reference pan with similar configuration. In this study, commercial solid fat 
index (SFI) aluminum pans were used and the experiment was conducted with an open 
pan. The samples were weighed and loaded into the pans. The sample is subjected to a 
Heat-Cool-Heat (HCH) cycle. We started at 28
o
C and heated to 40
o
C above the melt 
temp, i.e. the extrapolated onset temperature and cooled to 40
o
C below the melt 
temperature at a rate of 10
o
C min
-
¹. The data is analyzed using TAI Universal Analysis 
software. 
      The TA Instruments (TAI) Dielectric Analyzer 2970 was used for dielectric analysis 
of the samples over a wide range of frequencies from 0.1 to 100,000 Hz and temperatures 
from –50 to 300oC. Other parameters of the instrument included: the heating rate, purge 
gas, and liquid nitrogen cooling when necessary. The single surface gold ceramic 
interdigitated sensors were used (Fig 25). A sample size of 2 to 6mg of each drug was 
evaluated. The sample was properly weighed prior to the experiment. The shed snake 
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skin was soaked in pH buffer 7.4 for 10 to 12hrs before the experiment. The weighed 
sample is then evenly loaded onto the cut portion of pig skin and top portion of the shed 
snake skin which is carefully placed on the electrode (Fig 26). Then the sample is 
subjected to heating at a rate of 10°C min
-1
 up to 37
o
C and then kept isothermal for 40 
min at that temperature with nitrogen as a purge gas at a flow rate of 50mL min
-1
. The 
frequency range was selected from 0.1 to 30,000 Hz. The electrical response of the 
sample is recorded and the samples were analyzed. After each experiment, the skin is 
safely discarded and the electrode is soaked in an appropriate solvent for the drug 
(Risperidone and Quetiapine Fumarate in Methanol and Olanzapine in 0.1M H2SO4) for 
an hour. The residue in solution is then collected in a glass vial for UV analysis.  For each 
drug, two separate DEA studies were conducted and two separate residue samples were 
collected from those studies.  Similarly, two negative controls were run in the DEA 
apparatus with no applied electric field and these samples were also collected using the 
same method described above.  
 
                  
Figure 25 Single surface electrode 
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Figure 26 Shed snake skin with drug 
     The Cary 50 B10 UV-Visible spectrophotometer is used to evaluate the concentration 
of the drug throughput. For this study stock solutions of known drug concentration were 
prepared   using approximately 2 to 6 mg of each drug in a drug soluble solvent. A 
calibration curve was developed from the above stock solutions with measured 
absorbance vs. concentration of each drug at a particular wavelength (Olanzapine at 363 
nm, Risperidone at 280 nm and Quetiapine Fumarate at 303 nm). Two test samples and 
two control samples of unknown drug concentration of each drug collected in the vials 
were screened by UV spectroscopy. These samples were scanned and the absorbencies 
measured were fit into the standard calibration curve. Thus the unknown concentration of 
the sample is interpolated from the calibration curve or can be derived from the Beer-
Lambert law and is compared with the negative control sample. 
5.3 Results and Discussion 
5.3.1 DSC Evaluation 
     DSC revealed the purity of the three drugs tested in our study. In comparison of the 
melt temperature (Tm) measured to the literature value, the relative purity can be 
ascertained. The three drugs in this study, Olanzapine, Risperidone and Quetiapine 
fumarate were observed to have melting temperatures same as that of literature with the 
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correlation co-efficient of 0.98. The DSC protocol also aids in defining the ability of the 
crystalline solid to recrystallize or remain amorphous and produce a glass transition 
temperature. The DSC profiles of the three drugs are listed below. Risperidone shown 
below (Fig 28) illustrates the Heat-Cool-Heat cycle in which it happens to recrystallize 
upon cooling and melting upon reheating which confirms it to be a crystalline material. 
Whereas, Olanzapine (Fig 27) and Quetiapine Fumarate (Fig 29) do not recrystallize 
upon cooling, thus exhibiting their amorphicity. The heat of fusion (∆Hf), melting 
temperature (Tm) peak melt temperature (Tmp), heat of crystallization (∆Hc), 
crystallization temperature (Tc), peak crystallization temperature (Tcp) and glass transition 
temperature (Tg) were determined for all the three drugs and listed in Table 9. The drugs 
used in this study are probably >99%w pure. 
 
Figure 27 DSC profile of Olanzapine 
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Figure 28 DSC profile of Risperidone 
 
Figure 29 DSC profile of Quetiapine Fumarate 
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Table 9 DSC thermal properties of BPD drugs 
Cycle Values Olanzapine Risperidone Quetiapine Fumarate 
 Literature Value 195 170 174 
Heat1 Tm (
o
C) 194 170 174 
 Tmp (
o
C) 196 172 176 
 ∆Hf (
o
C) 107 90 122 
Cool Tc (
o
C) - 138 - 
 Tcp (
o
C) - 133 - 
 ∆Hc - 73 (81%) - 
Heat2 Tm (
o
C) - 168 - 
 Tmp (
o
C) - 171 - 
 Tg (
o
C) 73 - 54 
 ∆Hf - 80 (89%) - 
 
     The Risperidone Tm from the literature is identical to that measured in this study, i.e. 
170°C. This measurement implies that Risperidone is very pure. The difference between 
the Tmp and Tm is 2°C which also is interpreted as a measurement of a pure chemical. 
The variation of the Tm and Tc is 32°C is a physical property of Risperidone, that is, the 
super cooling of this chemical. The variation of the melt and crystallization heats 
identifies the crystallization of only 81% of the melt. In the second heat of this sample the 
heat of fusion was 89% of the first heat. Crystallization is a kinetic time dependent 
process and with more time in this DSC protocol more material crystallized from the 
amorphous phase and produced a higher crystalline content.   
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     The Olanzapine and Quetiapine melting temperatures were also identical to those 
published in the literature and are highly pure (>99%w) drugs. Both of these active 
pharmacy ingredients APIs did not recrystallize and upon further cooling and heating 
produced an amorphous phase only with glass transitions measured at 73°C and 54°C 
respectively for Olanzapine and Quetiapine Fumarate. 
5.3.2 Dielectric Analysis:  
     From the dielectric profiles of each drug obtained, the log conductivity (pScm
-1
) 
values were plotted against log frequency (Hz). The frequency range was selected from 
0.1 to 30,000 Hz. For each drug, the conductivity & log frequency values were taken at 
10, 20 and 35 min and were plotted. In this Debye plot, it is observed that the three drugs 
exhibited a marked change in the slope at about a frequency of 100 Hz (shed snake skin) 
which is called the critical frequency and 1000 Hz (pig skin) where the drug is almost 
delivered and levels off. The change is interpreted as a measure of the onset of drug 
throughput using the shed snake skin and pig skin as the animal models.  
5.3.2.1 Snake skin:  
 
Figure 30 DEA profile of Olanzapine at 10 min; 30,000Hz; Iso at 37°C for 40 min 
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Figure 31 DEA profile of Olanzapine at 10 min; before change 
 
 
 
Figure 32 DEA profile of Olanzapine at 10 min after change 
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     The Debye plot of Olanzapine plotted log frequency vs. log conductivity is illustrated 
in Fig 30 at 10 min, with a correlation co-efficient of 0.98. Fig 31 and Fig 32 indicate the 
slopes before and after the critical frequency at 10 min. 
 
Figure 33 DEA profile of Olanzapine; 30,000Hz, Iso at 37°C for 40 min; 20 min 
 
Figure 34 DEA profile of Olanzapine at 20 min; before change 
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Figure 35 DEA profile of Olanzapine at 10 min; after change 
 
 
 
Figure 36 DEA profile of Olanzapine at 35 min; 30,000Hz; Iso at 37°C for 40 min 
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Figure 37 DEA profile of Olanzapine at 35 min; before change 
 
 
 
 
Figure 38 DEA profile of Olanzapine at 35 min; after change 
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Figure 39 DEA profile of Risperidone at 10 min; 30,000Hz; Iso at 37°C for 40 min 
 
 
 
Figure 40 DEA profile of Risperidone at 10 min; before change 
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Figure 41 DEA profile of Risperidone at 10 min; after change 
 
 
 
Figure 42 DEA profile of Risperidone at 20 min; 30,000Hz; Iso at 37°C for 40 min 
y = 0.8802x - 2.3321
R² = 0.9965
-1
-1
0
1
1
2
2
0 1 2 3 4 5
L
o
g
 C
o
n
d
u
ct
iv
it
y
 (
p
S
cm
⁻¹
)
Log Frequency (Hz)
Risperidone at 37 C; 10; - after change
y = 0.762x - 2.075
R² = 0.992
-4
-3
-3
-2
-2
-1
-1
0
1
1
2
-2 -1 0 1 2 3 4 5
L
o
g
 C
o
n
d
u
ct
iv
it
y
 (
p
S
cm
⁻¹
)
Log Frequency (Hz)
Risperidone Iso at 37C - 20 min
68 
 
 
Figure 43 DEA profile of Risperidone at 20 min; before change 
 
 
 
Figure 44 DEA profile of Risperidone at 20 min; after change 
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Figure 45 DEA profile of Risperidone at 35 min; 30,000Hz; Iso at 37°C for 40 min 
 
 
 
Figure 46 DEA profile of Risperidone at 35 min; before change 
y = 0.8144x - 2.2822
R² = 0.9902
-4
-3
-2
-1
0
1
2
-2 -1 0 1 2 3 4 5
L
o
g
 C
o
n
d
u
ct
iv
it
y
 (
p
S
cm
⁻¹
)
Log Frequency (Hz)
Risperidone Iso at 37C - 35min
y = 0.681x - 2.222
R² = 0.998
-4
-3
-3
-2
-2
-1
-1
0
-2 -1 -1 0 1 1 2 2 3
L
o
g
 C
o
n
d
u
ct
iv
it
y
 (
p
S
cm
⁻¹
)
Log Frequency (Hz)
Risperidone Iso at 37 C; 35; before change
70 
 
 
Figure 47 DEA profile of Risperidone at 35; after change 
 
 
Figure 48 DEA profile of Quetiapine Fumarate at 10 min; 30,000Hz; Iso at 37°C for 40 
min 
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Figure 49 DEA profile of Quetiapine Fumarate at 10 min; before change 
 
 
 
Figure 50 DEA profile of Quetiapine Fumarate at 10 min; after change 
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Figure 51 DEA profile of Quetiapine Fumarate at 20 min; 30,000Hz; Iso at 37°C for 40 
min 
 
 
Figure 52 DEA profile of Quetiapine Fumarate at 20 min; before change 
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Figure 53 DEA profile of Quetiapine Fumarate at 20 min; after change 
 
 
 
Figure 54 DEA profile of Quetiapine Fumarate at 35 min; 30,000Hz; Iso at 37°C for 40 
min 
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Figure 55 DEA profile of Quetiapine Fumarate at 35 min; before change 
 
 
 
Figure 56 DEA profile of Quetiapine Fumarate at 35 min; after change 
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     From the data taken at 10, 20 and 35 min, data at 35min showed improved results. 
Olanzapine and Risperidone have an increased percentage (12 to 70%) of rates of change 
of log conductivity vs. log frequency which is interpreted as a positive sign of drug 
transport (see Table 10). 
Table 10 Analysis of DEA curve slope data to rank drug transport in shed snake skin 
Drugs Slope 1 Slope 2 
Ratio 
(S2/S1) 
% increase of 
S2 vs. S1 
Olanzapine 0.500 0.827 1.70 70 
Risperidone 0.681 0.988 1.45 45 
Quetiapine Fumarate 0.732 0.817 1.12 12 
Note: S1-Slope 1, S2-Slope2; S2 vs. S1 = Delta log conductivity/delta log frequency 
5.3.2.2 Pig skin
 
Figure 57 DEA profile of Olanzapine at 10 min; 30,000Hz; Iso at 37°C for 40 min 
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Figure 58 DEA profile of Olanzapine at 20 min; 30,000Hz; Iso at 37°C for 40 min 
 
 
 
Figure 59 DEA profile of Olanzapine at 35 min; 30,000Hz; Iso at 37°C for 40 min 
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Figure 60 DEA profile of Risperidone at 20 min; 30,000Hz, Iso at 37°C for 40 min 
 
 
 
Figure 61 DEA profile of Risperidone at 35 min; 30,000Hz; Iso at 37°C for 40 min 
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Figure 62 DEA profile of Quetiapine Fumarate at 10 min; 30,000Hz; Iso at 37°C for 40 
min 
 
 
Figure 63 DEA profile of Quetiapine Fumarate at 20 min; 30,000Hz; Iso at 37°C for 40 
min 
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Figure 64 DEA profile of Quetiapine Fumarate at 35 min; 30,000Hz; Iso at 37°C; Iso for 
40 min 
     The Debye plot data at 35 min provided improved results. We discovered that the 
DEA curve resulting from the drug through put with the pig skin membrane did not have 
an apparent critical frequency. Therefore the interpretation of the log conductivity vs. log 
frequency curve slope is related to the delivery of the BPD drugs in our testing. It is our 
experience with a lidocaine patch and DEA delivery that the drug is essentially delivered 
when the DEA slope or rate levels off e.g. see fig 64 at 8000 to 10000 Hz. The resulting 
electrified membrane delivery is significantly enhanced with the moist pig skin model vs. 
the dry shed snake skin model. The proof of concept is based on the UV analysis where 
the drug identity is set by the drug absorbance peak value of stock sample not varying 
from the test solution peak (see fig 67 and fig 68).  
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Figure 65 Olanzapine stock solution- peak observed at 363nm 
 
 
Figure 66 Olanzapine test sample solution- peak observed at 362nm 
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Figure 67 Risperidone standard stock solution scan- peak observed at 280nm 
 
Figure 68 Risperidone test solution scan- peak observed at 282 
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Figure 69 Quetiapine Fumarate stock solution scan- peak observed at 303nm 
 
Figure 70 Quetiapine Fumarate test solution scan- peak observed at 303nm 
     The normalized BPD drug results were obtained subtracting the non-electrical field 
control due to diffusion. The average of normalized drug delivery is taken for all the three 
drugs with shed snake skin and pig skin. (See table 11 for shed snake skin) and (See table 
12 for pig skin). 
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Table 11 End-point conductivity and drug throughput of shed snake skin 
Drug 
Sample 
(Drug 
Conc. 
mg ml
-1
) 
Control 
(Drug 
Conc. 
mg ml
-1
) 
Difference 
Average 
of 
Difference 
(Drug 
Conc. 
mg ml
-1
) 
End point 
Conductivity 
(pScm⁻¹) 
(10¹) 
Olanzapine1 
Olanzapine2 
0.75 
0.085 
0.031 
0.081 
0.72 
0.77 
0.74 54.3 
Risperidone1 
Risperidone2 
0.103 
0.156 
0 
0 
0.103 
0.156 
0.13 
46.2 
 
Quetiapine F1 
Quetiapine F2 
 
Fumarate.2 
0.035 
0.176 
0 
0 
0.035 
0.176 
0.105 
56.3 
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Table 12 End-point conductivity and drug throughput in pig skin 
Drug 
Sample 
(Drug 
Conc. 
mg ml
-1
) 
Control 
(Drug 
Conc. 
mg ml
-1
) 
Difference 
Average 
of 
Difference 
(Drug 
Conc. 
mg ml
-1
) 
End point 
Conductivity 
(pScm⁻¹)(10⁶) 
Olanzapine1 
Olanzapine2 
2.75 
2.96 
0.51 
0.08 
2.24 
2.50 
2.40 3.32 
Risperidone1 
Risperidone2 
6.70 
6.60 
0 
0 
6.70 
6.60 
6.65 
2.77 
 
Quetiapine F1 
Quetiapine F2 
 
0.0085 
0.014 
0 
0 
0.0085 
0.014 
0.01 
1.81 
 
 
 
     The conductivity associated with drug through put with a pig skin model was 
significantly greater (10
6 
pS cm⁻¹) with the shed snake skin (101pS cm⁻¹) (see table 13). 
They are to be compared to the modified (subtracting the control values) UV analysis of 
the measured through put concentrations (mg ml⁻¹). In summary, the average through put 
conductivity increased to 2.6 *10
6
 pS cm⁻¹ associated with the 3.02 mg ml⁻¹ drug 
delivered to the underside of the pig skin membrane. The ionic conductivity/average of 
difference of shed snake skin and pig skin were taken and there was no correlation 
between the values obtained from two skins (see table 14). 
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Table 13 Drug throughput and conductivity - shed snake skin and pig skin 
 Shed snake skin Pig skin 
Drug 
Drug 
Conc. 
mg ml⁻¹ 
Conductivity 
(pScm⁻¹) (10¹) 
Drug Conc. 
mg ml⁻¹ 
Conductivity 
(pScm⁻¹) (10⁶) 
Olanzapine 0.74  2.40  
Olanzapine  5.43  3.32 
Risperidone 0.13  6.65  
Risperidone  4.62  2.77 
Quetiapine 
Fumarate.1 
0.11  0.01  
Quetiapine 
Fumarate.2 
 
 5.63  1.81 
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Table 14 Summary of results 
Drugs 
Ionic Conductivity 
(pS cm⁻¹)/ 
Average of 
difference (mg 
ml⁻¹) (snake) 
Ionic Conductivity 
(pS cm⁻¹)/ 
Average of 
difference (mg 
ml⁻¹) (pig) 
Structure of the drug 
Olanzapine 54/0.74=73 32/2.40=0.83 
 
Risperidone 46/0.13=354 2.8/6.6=4.24 
 
Quetiapine 
Fumarate 
56/0.11=509 18/.01=1,810 
 
 
5.4 Conclusion  
     This study for three structurally different drugs produced varying results of drug 
through put across bio membranes e.g. part one- shed snake skin and part two- pig skin. It 
is our opinion that a positive slope change, part one- shed snake skin, above the critical 
frequency in the log conductivity vs. log frequency curve implies good drug transport for 
this skin model. This fact has been substantiated by determining the drug enhanced 
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throughput of 12 to 70% for the three BPD drugs by UV spectroscopy on the delivery 
side of the membrane. 
     UV analysis of the drug samples compared against the control samples yielded 
positive results of drug delivery. A calibration curve prepared from the stock solutions of 
each drug resulted in an R
2
 value of about 0.99. The test samples analyzed were found to 
contain the drug delivered through the skin. The enhanced slope above the critical 
frequency is evidence that this protocol for drug transport is effective. The variation in 
the mg mL
-1
 in the observed throughput is ±17% and has a cause and effect relationship 
with the conductivity.   
     The study of three structurally different drugs tested with pig skin yielded measured 
delivery of an average 0.347 mg mL
-1
 in conjunction with an applied field. The pig skin 
conductivity is influenced by the moist condition of this membrane and shows higher 
conductivity values and the shed snake skin shows much lesser conductivity values 
probably related due to the extreme dry nature of this model membrane. Finally the drug 
delivery through the membrane is observed and confirmed but there is no correlation 
between the pig skin and snake skin results and the delivery is drug dependent. 
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CHAPTER VI 
FUTURE DIRECTIONS 
 
 Our quest is to correlate drug transport under an electric field with varying animal 
model skins. Shed Snake Skin and Pig skin have enhanced this study and paved 
the way for transdermal delivery of these BPD drugs.  
 Additional model skins for the immediate future are a mouse bladder skin for 
cancer drugs and rabbit eye sclera for anti-tumor drug development for age related 
macro degeneration. The latter is already in progress with the Cleveland Clinic 
Foundation.  
 A skin model variable, that needs exploration, is the skin thickness vs. through put 
efficacy as well as time and field.  
 Other viable areas of research will include the effect of penetration enhancers, e.g. 
acetone is currently being used with nitroglycerin transdermal patches for cardiac 
patients
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